TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models

Journal of Immunology

Volumn 184, Issue 4, 2010, Pages 2156-2165

  Verma, Bhavna ^a   Neethling, Francisca A ^b   Caseltine, Shannon ^b   Fabrizio, Ginger ^b   Largo, Sherly ^b   Duty, J Andrew ^b   Tabaczewski, Piotr ^c   Weidanz, Jon A ^a,b  

^a TEXAS TECH UNIVERSITY   (United States)

^b Receptor Logic Inc   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; ANTINEOPLASTIC AGENT; CHORIONIC GONADOTROPIN BETA SUBUNIT; GLYCYLVALYLLEUCYLPROLYLALANYLLEUCYLPROLYLGLUTAMINYLVALINE; HLA A2 ANTIGEN; MONOCLONAL ANTIBODY; RL4B TCRM MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; EPITOPE; GROWTH INHIBITOR; HLA A ANTIGEN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; PEPTIDE FRAGMENT; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER INHIBITION; CANCER MODEL; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; TUMOR CELL LINE; TUMOR GROWTH; ANIMAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; BIOSYNTHESIS; BREAST TUMOR; CELL LINE; CYTOTOXICITY TEST; GENE TARGETING; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR MIMICRY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; GENE TARGETING; GROWTH INHIBITORS; HLA-A ANTIGENS; HUMANS; MICE; MICE, NUDE; MOLECULAR MIMICRY; PEPTIDE FRAGMENTS; TUMOR MARKERS, BIOLOGICAL;

EID: 77949895698     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902414     Document Type: Article

References (62)

1. Knuth, A., T. Wölfel, E. Klehmann, T. Boon, and K. H. Meyer zum Büschenfelde. 1989. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. USA 86: 2804-2808.
2. Barth, R. J., Jr., J. J. Mulé, A. L. Asher, M. G. Sanda, and S. A. Rosenberg. 1991. Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor. J. Immunol. Methods 140: 269-279.
3. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347-352.
4. Cole, D. J., D. P. Weil, P. Shamamian, L. Rivoltini, Y. Kawakami, S. Topalian, C. Jennings, S. Eliyahu, S. A. Rosenberg, and M. I. Nishimura. 1994. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res. 54: 5265-5268.
5. Topalian, S. L., L. Rivoltini, M. Mancini, N. R. Markus, P. F. Robbins, Y. Kawakami, and S. A. Rosenberg. 1994. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA 91: 9461-9465.
6. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154: 3961-3968.
7. Zhai, Y., J. C. Yang, Y. Kawakami, P. Spiess, S. C. Wadsworth, L. M. Cardoza, L. A. Couture, A. E. Smith, and S. A. Rosenberg. 1996. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 156: 700-710.
8. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56: 4749-4757.
9. Overwijk,W.W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self "-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188: 277-286.
10. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
11. Hughes, M. S., Y. Y. Yu, M. E. Dudley, Z. Zheng, P. F. Robbins, Y. Li, J. Wunderlich, R. G. Hawley, M. Moayeri, S. A. Rosenberg, and R. A. Morgan. 2005. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16: 457-472.
12. Cohen, S., J. Haimovich, and N. Hollander. 2009. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. J. Immunol. 182: 1667-1673.
13. Svane, I. M., A. E. Pedersen, J. S. Johansen, H. E. Johnsen, D. Nielsen, C. Kamby, S. Ottesen, E. Balslev, E. Gaarsdal, K. Nikolajsen, and M. H. Claesson. 2007. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol. Immunother. 56: 1485-1499.
14. Dean-Colomb, W., and F. J. Esteva. 2008. Her2-positive breast cancer: herceptin and beyond. Eur. J. Cancer 44: 2806-2812.
15. Nahta, R., M. C. Hung, and F. J. Esteva. 2004. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64: 2343-2346.
16. Stein, R., Z. Qu, S. Chen, A. Rosario, V. Shi, M. Hayes, I. D. Horak, H. J. Hansen, and D. M. Goldenberg. 2004. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res. 10: 2868-2878.
17. Nishida, M., S. Usuda, M. Okabe, H. Miyakoda, M. Komatsu, H. Hanaoka, K. Teshigawara, and O. Niwa. 2007. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int. J. Oncol. 31: 29-40.
18. Raben, D., B. Helfrich, D. C. Chan, F. Ciardiello, L. Zhao, W. Franklin, A. E. Barón, C. Zeng, T. K. Johnson, and P. A. Bunn, Jr. 2005. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res. 11: 795-805.
19. Hurwitz, H. 2004. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin. Colorectal Cancer 4(Suppl 2): S62-S68.
20. Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350: 2335-2342.
21. Kimura, H., K. Sakai, T. Arao, T. Shimoyama, T. Tamura, and K. Nishio. 2007. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98: 1275-1280.
22. Shan, D., J. A. Ledbetter, and O. W. Press. 1998. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91: 1644-1652. (Pubitemid 28110329)
23. Fendly, B. M., M. Winget, R. M. Hudziak, M. T. Lipari, M. A. Napier, and A. Ullrich. 1990. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50: 1550-1558.
24. Carter, P., L. Presta, C. M. Gorman, J. B. Ridgway, D. Henner, W. L. Wong, A. M. Rowland, C. Kotts, M. E. Carver, and H. M. Shepard. 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89: 4285-4289.
25. Rodriguez-Pinto, D., J. Sparkowski, M. P. Keough, K. N. Phoenix, F. Vumbaca, D. K. Han, E. D. Gundelfinger, P. Beesley, and K. P. Claffey. 2009. Identification of novel tumor antigens with patient-derived immune-selected antibodies. Cancer Immunol. Immunother. 58: 221-234.
26. Conrotto, P., C. Roesli, J. Rybak, P. Kischel, D. Waltregny, D. Neri, and V. Castronovo. 2008. Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int. J. Cancer 123: 2856-2864.
27. Siva, A. C., R. E. Kirkland, B. Lin, T. Maruyama, J. McWhirter, F. Yantiri-Wernimont, K. S. Bowdish, and H. Xin. 2008. Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells. J. Immunol. Methods 330: 109-119.
28. Gudowius, S., K. Recker, H. J. Laws, U. Dirksen, A. Tröger, U. Wieczorek, S. Furlan, U. Göbel, and H. Hanenberg. 2006. Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin. Padiatr. 218: 327-333.
29. Hayashi, E., Y. Matsuzaki, G. Hasegawa, T. Yaguchi, S. Kurihara, T. Fujita, T. Kageshita, M. Sano, and Y. Kawakami. 2007. Identification of a novel cancer-testis antigen CRT2 frequently expressed in various cancers using representational differential analysis. Clin. Cancer Res. 13: 6267-6274.
30. Xing, Q., X.W. Pang, J. R. Peng, Y. H. Yin, Y. Li, X. Yu, S. P. Zhou, Y. Zhang, and W. F. Chen. 2008. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587. Biochem. Biophys. Res. Commun. 372: 331-335.
31. Kessler, J. H., and C. J. Melief. 2007. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21: 1859-1874.
32. Weidanz, J. A., T. Nguyen, T. Woodburn, F. A. Neethling, M. Chiriva-Internati, W. H. Hildebrand, and J. Lustgarten. 2006. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J. Immunol. 177: 5088-5097.
33. Weidanz, J. A., P. Piazza, H. Hickman-Miller, D.Woodburn, T. Nguyen, A.Wahl, F. Neethling, M. Chiriva-Internati, C. R. Rinaldo, and W. H. Hildebrand. 2007. Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J. Immunol. Methods 318: 47-58.
34. Cohen, C. J., N. Hoffmann, M. Farago, H. R. Hoogenboom, L. Eisenbach, and Y. Reiter. 2002. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 62: 5835-5844.
35. Denkberg, G., C. J. Cohen, A. Lev, P. Chames, H. R. Hoogenboom, and Y. Reiter. 2002. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 99: 9421-9426.
36. Andersen, P. S., A. Stryhn, B. E. Hansen, L. Fugger, J. Engberg, and S. Buus. 1996. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc. Natl. Acad. Sci. USA 93: 1820-1824.
37. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726.
38. Chames, P., S. E.Hufton, P.G.Coulie, B.Uchanska-Ziegler, and H. R.Hoogenboom. 2000. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc. Natl. Acad. Sci. USA 97: 7969-7974.
39. Lev, A., G. Denkberg, C. J. Cohen, M. Tzukerman, K. L. Skorecki, P. Chames, H. R. Hoogenboom, and Y. Reiter. 2002. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 62: 3184-3194.
40. Neethling, F. A., V. Ramakrishna, T. Keler, R. Buchli, T. Woodburn, and J. A. Weidanz. 2008. Assessing vaccine potency using TCRmimic antibodies. Vaccine 26: 3092-3102.
41. Wittman, V. P., D. Woodburn, T. Nguyen, F. A. Neethling, S. Wright, and J. A. Weidanz. 2006. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J. Immunol. 177: 4187-4195.
42. Stenman, U. H., H. Alfthan, and K. Hotakainen. 2004. Human chorionic gonadotropin in cancer. Clin. Biochem. 37: 549-561.
43. Kuorelahti, A., S. Rulli, I. Huhtaniemi, and M. Poutanen. 2007. Human chorionic gonadotropin (hCG) up-regulates wnt5b and wnt7b in the mammary gland, and hCGbeta transgenic female mice present with mammary Gland tumors exhibiting characteristics of the Wnt/beta-catenin pathway activation. Endocrinology 148: 3694-3703.
44. Hämäläinen, T., J. Kero, M. Poutanen, and I. Huhtaniemi. 2002. Transgenic mice harboring murine luteinizing hormone receptor promoter/beta-galactosidase fusion genes: different structural and hormonal requirements of expression in the testis, ovary, and adrenal gland. Endocrinology 143: 4096-4103.
45. Bièche, I., V. Lazar, C. Noguès, T. Poynard, Y. Giovangrandi, D. Bellet, R. Lidereau, and M. Vidaud. 1998. Prognostic value of chorionic gonadotropin beta gene transcripts in human breast carcinoma. Clin. Cancer Res. 4: 671-676.
46. Bièche, I., S. Tozlu, I. Girault, P. Onody, K. Driouch, M. Vidaud, and R. Lidereau. 2004. Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. Carcinogenesis 25: 405-411.
47. Arai, K., K. Yoshinari, K. Matsumoto, and H. Misaki. 1998. An ELISA to determine the biodistribution of human monoclonal antibody in tumor-xenografted SCID mice. J. Immunol. Methods 217: 79-85.
48. Topley, P., D. C. Jenkins, E. A. Jessup, and J. N. Stables. 1993. Effect of reconstituted basement membrane components on the growth of a panel of human tumour cell lines in nude mice. Br. J. Cancer 67: 953-958. (Pubitemid 23147485)
49. Mullen, P., A. Ritchie, S. P. Langdon, and W. R. Miller. 1996. Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines. Int. J. Cancer 67: 816-820.
50. Card, K. F., S. A. Price-Schiavi, B. Liu, E. Thomson, E. Nieves, H. Belmont, J. Builes, J. A. Jiao, J. Hernandez, J. Weidanz, et al. 2004. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol. Immunother. 53: 345-357.
51. Held, G., M. Matsuo, M. Epel, S. Gnjatic, G. Ritter, S. Y. Lee, T. Y. Tai, C. J. Cohen, L. J. Old, M. Pfreundschuh, et al. 2004. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur. J. Immunol. 34: 2919-2929.
52. Cohen, C. J., O. Sarig, Y. Yamano, U. Tomaru, S. Jacobson, and Y. Reiter. 2003. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J. Immunol. 170: 4349-4361.
53. Thurber, G. M., M. M. Schmidt, and K. D. Wittrup. 2008. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60: 1421-1434.
54. Thurber, G. M., S. C. Zajic, and K. D. Wittrup. 2007. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J. Nucl. Med. 48: 995-999.
55. Thurber, G. M., M. M. Schmidt, and K. D. Wittrup. 2008. Factors determining antibody distribution in tumors. Trends Pharmacol. Sci. 29: 57-61.
56. Tang, Y., J. Lou, R. K. Alpaugh, M. K. Robinson, J. D. Marks, and L. M. Weiner. 2007. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J. Immunol. 179: 2815-2823.
57. Epel, M., I. Carmi, S. Soueid-Baumgarten, S. K. Oh, T. Bera, I. Pastan, J. Berzofsky, and Y. Reiter. 2008. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur. J. Immunol. 38: 1706-1720.
58. Denkberg, G., A. Lev, L. Eisenbach, I. Benhar, and Y. Reiter. 2003. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J. Immunol. 171: 2197-2207. (Pubitemid 37025524)
59. Klechevsky, E., M. Gallegos, G. Denkberg, K. Palucka, J. Banchereau, C. Cohen, and Y. Reiter. 2008. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res. 68: 6360-6367.
60. Mosquera, L. A., K. F. Card, S. A. Price-Schiavi, H. J. Belmont, B. Liu, J. Builes, X. Zhu, P. A. Chavaillaz, H. I. Lee, J. A. Jiao, et al. 2005. In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein. J. Immunol. 174: 4381-4388.
61. Aguilar, Z., R. W. Akita, R. S. Finn, B. L. Ramos, M. D. Pegram, F. F. Kabbinavar, R. J. Pietras, P. Pisacane, M. X. Sliwkowski, and D. J. Slamon. 1999. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 18: 6050-6062.
62. du Manoir, J. M., G. Francia, S. Man, M. Mossoba, J. A. Medin, A. Viloria-Petit, D. J. Hicklin, U. Emmenegger, and R. S. Kerbel. 2006. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin. Cancer Res. 12: 904-916.